Table 1.
Poultry DNA vaccination against viruses.
| Pathogen | Host | Antigen | Route | Major immunological outcomes | References |
|---|---|---|---|---|---|
| Avian Influenza Virus | Chicken | HA (mainly) or H5 or H7 or M | IM Or IV + SC + IP Or ID/SC Or IM Or oral |
Stimulation of CD4+ and CD8+ T-cells, Th1 cytokines. Hemagglutinin inhibition. High levels of protection (up to 16 out of 17 chickens protected from a severe challenge). | [6], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28] |
| Duck | HA | ID/IM | Induction of virus neutralizating antibodies and haemagglutination inhibition. | [10] | |
| Infectious Bursal Disease Virus | Chicken | VP2 or VP243 | IM Or IM + ID Or IM + IP Or oral Or In ovo/IM Or oral + eye |
High level of protection against an experimental challenge, up to 100%. | [5], [9], [29], [30], [31], [32], [33], [34], [35], [36] |
| Infectious Bronchitis Virus | Chicken | S1 and/or N and/or M or unique ORF with 7 epitopes | IM Or in ovo/IM |
60–90% of protection against an experimental challenge. | [7], [37], [38], [39], [40], [41] |
| Duck Hepatitis B Virus | Duck | preS/S and/or C | IM | Evaluation of new treatments based on DNA vaccination for humans. | [42], [43], [44], [45], [46], [47] |
| Avian Reovirus | Chicken | σB and/or σC | oral | 66.7–75% protection against experimental challenges. | [48], [92] |
| Chicken Anemia Virus | Chicken | VP1 and/or VP2 | IM | Induction of CD8+ T-cells, virus neutralization antibodies, IL-2 and IFN-γ. | [3], [52], [93] |
| Newcastle Disease Virus | Chicken | F and/or H | IN + IM Or IN Or IM |
High level of protection, up to 100% protection against an experimental challenge. | [13], [49], [72], [74], [77], [90] |
| Marek Disease Virus | Chicken | Herpesvirus genome | IM/ID | 55% of survivors after a severe experimental challenge. | [50] |
| Infectious Laryngotracheitis Virus | Chicken | gB | IM | Decrease of mortality from 65–75% to 0%. | [12] |
| Reticuloendotheliosis Virus | Chicken | Gp90 | IM | Induction of neutralizing antibodies. Proliferation and production of IL4 and IFN-γ by lymphocytes. Partial control of viremia after challenge (13/15 vs 2/15 in the control group). | [51] |
| Turkey Rhinotracheitis Virus | Turkey | F and N | IM | Reduction in the level of virus shedding and induction of antibodies Decrease of animals presenting clinical symptoms from 50–60% to 20–30%. |
[53] |
| Turkey Coronavirus | Turkey | 4F/4R fragment of TCoVS | IM | Humoral immune response and decrease of turkeys showing clinical signs from 5/5 to 1/5 or 2/5. | [54] |
| Duck Enteritis Virus | Duck | gB, gC, gD or UL24 | IG Or IM Or IN |
IgG, IgA and neutralizing antibodies. Up to 80% of survivors after challenge. | [1], [86], [94] |
| Duck Plague Virus | Duck | gC | IM Or ID |
Induction of virus specific serum IgG and neutralizing antibodies as well as lymphoproliferation. | [55] |